EXCLUSIVE: Harmony Bio Responds To Short Report, Tells Benzinga It Disagrees With Assertions

Harmony Biosciences Holdings Inc HRMY shares fell almost 20% after Scorpion Capital filed a Citizen's Petition with the FDA requesting the withdrawal of approval of Wakix (pitolisant).
When Benzinga reached out to learn more, Harmony Biosciences Spokesperson exclusively told Benzinga, "We are aware of this report from an activist investor and disagree with their assertions. We remain committed to helping those who live with devasting rare diseases, and our science has been subject to peer review and received global regulatory approval. We'll continue to innovate and develop safe and effective medications for those in need."
"With regards to a Citizen Petition, we have not seen anything filed publicly at this time," the spokesperson added.
The Short seller report added that "Harmony's drug Wakix (pitolisant) is a repeat of the Seldane (terfenadine) saga, another histamine antagonist that the FDA pulled from the market and which is the poster child for cardiac toxicity via fatal QT prolongation/arrhythmia. Wakix is worse."
Price Action: HRMY shares are down 23.2% at $31.89 on the last check Tuesday.

Overview Rating:

Good

0100